Intrinsiqq
LB Pharmaceuticals Inc. logo

LB Pharmaceuticals Inc.

LBRX

⊜ Compare

As of December 31, 2025, certain of our former and current officers and their affiliates held 1.13% of the future royalties. Components of Results of Operations Revenue To date, we have not recognized any revenues, including revenues from product sales.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$1.28B
EPS$22.86
P/E1.74
P/FCF-15.47
EV/EBITDA–
FCF Yield–
Div. Yield–
Net Debt/FCF3.9x
LB Pharmaceuticals Inc. intrinsic value
52-Week Range
$14.61$49.48

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$86M

▲ +60.1% YoY

Op. Margin

–

ROIC

–

Cash Flow & Balance Sheet

FCF (TTM)

-$83M

▲ +34.5% YoY

Op. Cash Flow (TTM)

-$82M

▲ +33.6% YoY

Net Debt

-$323M

Net Cash Position

Cash & Equiv.

$328M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with LBRX

CompareIntrinsic value
NGNENeurogene Inc.
$27.55-4.41%10
MREOMereo BioPharma Group plc
$0.29-3.97%10
COYACoya Therapeutics Inc.
$3.61-9.30%10
PRLDPrelude Therapeutics Incorporated
$3.88-5.37%40
PLRXPliant Therapeutics Inc.
$0.86-0.13%10
AARDAardvark Therapeutics, Inc.
$1.36-5.56%10
ORMPOramed Pharmaceuticals Inc.
$4.11-2.84%35
NTHINeonC Technologies Holdings
$3.26+4.49%10

Held by ETFs

LBRX is in 23 US ETFs. The largest of them, with LBRX's weight in each:

LB Pharmaceuticals (LBRX) in two numbers

Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
1.74
Price to free cash flow -15.47.
Financials

Questions about LB Pharmaceuticals

Is LB Pharmaceuticals (LBRX) overvalued?

LB Pharmaceuticals trades at 1.74 times earnings. Intrinsiqq's fair value calculator has no opening value for LBRX, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.

Does LB Pharmaceuticals (LBRX) pay a dividend?

No. LB Pharmaceuticals (LBRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 5 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in LBRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LBRX

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.